Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Am J Transplant. 2019 Jul 8;19(12):3356–3366. doi: 10.1111/ajt.15482

Figure 4a, 4b, 4c & 4d.

Figure 4a, 4b, 4c & 4d.

Figure 4a, 4b, 4c & 4d.

Figure 4a, 4b, 4c & 4d.

Figure 4a, 4b, 4c & 4d.

(4a) Receiver Operating Characteristic Curves from biopsies for AR vs. TX. ROC in solid line represents the performance of the AR vs TX biopsy classifier on the Brazilian Validation Set (AUC - 0.94) and the ROC in the dotted line represents the performance of the AR vs TX biopsy classifier on the TGCG Training Set (AUC - 0.94). (4b) Receiver Operating Characteristic Curves from biopsies for CR vs. TX. ROC in solid line represents the performance of the CR vs TX biopsy classifier on the Brazilian Validation Set (AUC - 0.94) and the ROC in the dotted line represents the performance of the CR vs TX biopsy classifier on the TGCG Training Set (AUC - 0.90). (4c) Receiver Operating Characteristic Curves from peripheral blood for AR vs. TX. ROC in solid line represents the performance of the AR vs TX blood classifier on the Brazilian Validation Set (AUC - 0.97) and the ROC in the dotted line represents the performance of the AR vs TX blood classifier on the TGCG Training Set (AUC - 0.66). (4d) Receiver Operating Characteristic Curves from peripheral blood for CR vs. TX. ROC in solid line represents the performance of the CR vs TX blood classifier on the Brazilian Validation Set (AUC - 0.97) and the ROC in the dotted line represents the performance of the CR vs TX blood classifier on the TGCG Training Set (AUC - 0.68). AR, Acute Rejection; CR, IFTA/Chronic Rejection; TX, transplant excellent.